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proposed as therapeutic agents because of their promising
preclinical features and good safety profile. However, their
introduction into clinical practice has been associated with a
suboptimal therapeutic profile. In this review, we address the
biodistribution of MSCs in preclinical studies with a focus on
the current understanding of the pharmacodynamics (PD)
and pharmacokinetics (PK) of MSCs as key aspects to overcome
unsatisfactory clinical benefits of MSC application. Beginning
with evidence of MSC biodistribution and highlighting PK
and PD factors, a new PK-PD model is also proposed. Accord-
ing to this theory, MSCs and their released factors are key
players in PK, and the efficacy biomarkers are considered rele-
vant for PD in more predictive preclinical investigations.
Accounting for the PK-PD relationship in MSC translational
research and proposing new models combined with better bio-
distribution studies could allow realization of the promise of
more robust MSC clinical translation.https://doi.org/10.1016/j.omtm.2019.05.004.
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E-mail: massimo.dominici@unimore.itRecently, there has been increasing interest in the use of adult stromal
progenitors—namely, mesenchymal stromal stem cells (MSCs)—for
the development of cell and gene therapies for several biomedical pre-
clinical and clinical applications. MSCs have promising features for
their ease of use in ex vivo manipulations and for their capacity to
generate a therapeutic benefit in early investigations.1,2
Although the bone marrow has been the main source of MSCs, they
have also been isolated from other tissues, including adipose tissue,
amniotic fluid, endometrial tissue, dental tissue, umbilical cord, and
Wharton’s jelly.3,4 MSCs have been defined as non-hematopoietic
progenitors able to self-renew,5 migrate to a site of injury,6,7 differen-
tiate into mesodermal lineages,8 modulate the immune response,9,10
and secrete anti-inflammatory molecules.11,12 These cells can also
be easily isolated from different animal species13 and preserved
ex vivo, and they are considered safe because of their low immunoge-
nicity after transplantation.14,15
For the last decade, MSCs have been considered advanced medicinal
therapy (AMT) and, therefore, compared with drugs; however, their
mechanism of action (MoA) and tissue distribution in several targetMolecular Therapy: Methods & C
This is an open access article under the CC BY-Ndiseases are still unexplored and not completely understood.16
Currently, the MoA of MSCs is believed to be associated with their
ability to engraft, differentiate, and/or release paracrine signals, but
the contribution of each of these properties remains unclear.17,18
Therefore, the MoA has been described as a complicated network
in which MSCs trigger different reactions that also involve other
nearby cells with the aim of generating the desired biological function
that is then related to a therapeutic effect.
How much whole cells per se or the released mediators are respon-
sible for the mentioned therapeutic effect is not yet completely known
and may also be related to the target disease and the microenviron-
ment. However, it has been observed that a direct injection of biomol-
ecules released byMSCs can provide a benefit above and beyond what
is conveyed by the transplanted cells alone.19,20 The factors released
by MSCs seem to be key players in the beneficial effects after cell
transplantation, with the difference being that the implanted cells
can constantly release these factors, whereas exogenous delivery of
MSC-derived biomolecules requires constant, or at least pro-
grammed, delivery in some manner similar to common pharmaceu-
tical drugs.21 These still unclear MSC functions and their related
bioactive molecules for the intended therapeutic profile pose a chal-
lenge to an exact definition of the biomarkers linked with an assess-
ment of MSCs’ MoA and efficacy.22 Additionally, it is known that
each disease has its own microenvironmental peculiarities (i.e.,
inflammatory cells, cytokines) that could differentially affect the bio-
logical functions of MSCs after in vivo transplantation.23–25.
This still obscure but intriguing scenario requires clarification of
the basic concepts of MSC drug development, including thelinical Development Vol. 14 September 2019 ª 2019 The Authors. 1
C-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Reviewpharmacokinetics (PK) and pharmacodynamics (PD) of the cells
themselves and their bioactive agents. However, studying PD aspects
of MSCs is difficult and results in unclear biomarker definition. Addi-
tionally, a substantial barrier to achieving good efficacy is the lack of
robust PK data for cells and mediators involved in the biological ac-
tivity.26 Increased knowledge of cell distribution after delivery could
help estimate the PK of MSCs and, consequently, define the dosing
regimen needed to reach the therapeutic effect. As of January 2019,
the number of clinical trials based onMSCs that are publicly available
in selected internet resources (https://www.clinicaltrials.gov/) exceeds
800, and many of these studies discuss the possible MoA of
MSCs,27–29 but data regarding MSC PK and biodistribution are still
scarce. For this reason, in this review, we consider PK aspects of
MSCs and present factors that may influence MSC-based PK studies
to conceive a new PK-PD model. We use the approach described by
Parekkadan and Milwid1,—the only described approach to date—as a
starting point for the new model.30
Biodistribution of MSCs in Preclinical Settings
Preclinical and clinical investigations have been performed with the
aim of investigating MSC tissue distribution, safety, and therapeutic
effect to ameliorate pathologic states.31,32 The following discussion
of a series of MSC preclinical studies conducted in the last 30 years
delineates fundamental aspects of MSC biodistribution.
MSCs Are Transplantable via the Intravenous Route and
Trapped in the Lungs
In 1983, Piersma et al.33 provided early pivotal evidence from a mu-
rine model of MSC biodistribution after intravenous (i.v.) transplan-
tation of cells tracked by chromosome marking. Most of the injected
cells reached the recipient’s bone marrow and remained in situwithin
3months after transplantation, indicating the ability of injectedMSCs
to specifically lodge in the host’s bone marrow.33 After those initial
findings, many preclinical rodent-based investigations were reported
(Table 1). In 1995, Pereira et al.34 provided the first evidence of MSC
lung localization following systemic administration. After culture,
cells were injected into irradiated mice and detected in the paren-
chyma of alveoli and bronchi.34 Subsequently, other studies were
performed to better understand this phenomenon and prevent pul-
monary entrapment by lung hemodynamic alterations to ultimately
increase MSC biodistribution to the target organ.35–38
Route of Administration and Vessel Size Influence Lung
Trapping
In 2001, Gao et al.35 infused rat bone marrowMSCs radiolabeled with
indium-111oxine through different routes and followed their distri-
bution using whole-body scanning and dynamic imaging. The main
aim of the study was to compare i.v., intra-arterial (i.a.), and intraper-
itoneal (i.p.) infusions. After i.a. and i.v. delivery, radioactivity was
first observed in the lungs and then, gradually, in the liver. Together,
these organs comprised approximately 50% of the infused radioac-
tivity, confirming the lungs as a primary compartment in MSC bio-
distribution in vivo. In an attempt to bypass lung localization, the
same authors introduced sodium nitroprusside as a vasoactive agent,2 Molecular Therapy: Methods & Clinical Development Vol. 14 Septembwhich led to a decrease in lung signal by 15% and an increase in liver
distribution, indicating that a simple change in vessel diameter is
linked to a different biodistribution pattern, indirectly suggesting a
pivotal role of vessel size as a factor contributing to MSC lung local-
ization. In that study, i.a. and i.v. administration did not show any sig-
nificant difference in cell distribution. However, after i.p. infusion,
lung radioactivity was negligible, confirming that extra-vascular de-
livery was able to bypass the pulmonary tract.35 Schrepfer et al.36
confirmed these findings in a murine model in which cells were moni-
tored by firefly luciferase and the green fluorescent dye 5-(and -6)-
carboxyfluorescein diacetate succinimidyl ester (CSFE) and tracked
post-mortem by histopathology of pulmonary sections. The authors
demonstrated that the mean size of the MSCs was larger than the
size of the pulmonary capillaries. Thus, large amounts of injected
MSCs could be trapped in lung capillaries, preventing access to other
organs. Further, lung localization could be reduced by a vasodilator.36
Intrinsic Properties and Microenvironmental Cues Affect MSC
Biodistribution
The findings related to MSC biodistribution seem to be limited by
vasculature-related issues, such as vessel size and pressure, and by still
unclear intrinsic MSC properties, such as cytoskeletal activity, migra-
tion capacity, or cell size, that affect specific organ localization. Niyi-
bizi et al.37 reported a graft of GFP-positive murine MSCs into
neonatal mice via a superficial temporal vein. The in vivo MSC
tracking was performed by fluorescence microscopy and revealed a
GFP signal in the lungs, liver, and bone 7 days after infusion. MSCs
persisted in the lungs up to 150 days post-transplantation, with evi-
dence of tissue-specific differentiation. Engrafted GFP-positive cells
were then harvested from bone and infused into secondary recipients.
Curiously, after systemic delivery of these bone-derived MSCs, cells
could only be detected in skeletal tissues and not in the lungs or liver,
indicating that intrinsicMSC properties and physiological microenvi-
ronmental cues were able to select specific MSC sub-clones associated
with a defined biodistribution pattern in the lack of pathological
conditions.37,39
The Role of Immunity in MSC Biodistribution
At the beginning of 2000, Liechty et al.40 described the engraftment of
humanMSCs after in utero transplantation into a fetal sheep with the
aim of assessing tissue distribution of human cells into an immuno-
deficient large animal model. PCR assays, immunohistochemistry,
and in situ hybridization were introduced to evaluate the presence
and differentiation of MSCs in mesenchymal tissues of the fetal sheep
for as long as 13 months. After xenotransplantation, MSCs under-
went site-specific differentiation into chondrocytes and in cardio-
myocytes, and, even after development of fetal immunocompetence,
MSCs maintained their underlying ability to differentiate in several
tissues and maintained their multipotentiality and immunological
advantage.40 On the basis of these data, researchers have investigated
the immunology of MSCs and their ability to evade and/or influence
the host immune system in relationship with immunosuppression
and/or immunoprivilege.41 The first is due to MSCs’ ability to sup-
press recipient immune cells,42,43 and the second is based on theer 2019
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Reviewnegligible expression of the major histocompatibility complex on the
surface of MSCs.44–46 Recent data have demonstrated an increased
level of human leukocyte antigen-DR isotype (HLA-DR) expression
that was irrelevant with regard to the MSC capacity to influence
lymphocyte proliferation.47 However, the low MSC engraftment after
transplantation may also be related to cell destruction by immune
recognition. Zangi et al.48 suggested that, although luciferase-labeled
marrow murine MSCs can retain mild immunosuppressive activity,
they do not completely evade the immune system and induce rejec-
tion and memory. Despite that fact, allogeneic MSCs exhibited longer
survival than skin fibroblasts, but their survival was shorter than that
observed in syngeneic or immune-deficient recipients. Thus, immu-
nogenicity may influence MSC biodistribution in vivo, and this
must be considered for accurate selection of the animal model.
More recently, some authors have suggested that immunosuppres-
sion by MSC may also be exerted after cell destruction, opening the
field to novel investigations aimed at a deeper understanding of
how dying MSC could be immunosuppressive.49
The Role of Inflammation and Cancer in MSC Biodistribution
Inflammatory signals may also affect MSC biodistribution. A paradig-
matic example is provided by Wang et al.,50 who studied the bio-
distribution of MSCs following both i.a. and i.v. infusion into 2
distinct bone marrow transplantation (BMT) settings: allogeneic
and syngeneic BMT. Biodistribution was measured by biolumines-
cence imaging (BLI) using luciferase-containing MSCs and by
99mTc-scintigraphic imaging. Immunohistochemistry and real-time
qPCR were also introduced to support in vivo data. MSC i.a. admin-
istration was followed by wider biodistribution through the body than
i.v. delivery, which was primarily characterized by lung localization.
Interestingly, MSC migration in the abdomen was more prominent
after i.a. delivery in the allogeneic model with gastrointestinal (GI)
acute graft versus host disease (GVHD). These data support i.a.
delivery of MSCs, further suggesting how microenvironmental cues,
such as an inflammatory milieu of GVHD, can influence MSC
biodistribution.
In addition, pathological conditions and related factors (i.e., cyto-
kines, chemokines) may influence cell biodistribution with conse-
quences for their therapeutic profile. Lee et al.51 demonstrated, in
non-obese diabetic (NOD)-severe combined immunodeficiency
(SCID) mice, that i.v. infused human MSCs ameliorate the outcome
of a myocardial infarction model. MSCs were visible by PCR in
infarcted hearts starting from 15 min after infusion; the visibility
peaked 1 day after infusion and then faded. However, a curative effect
was observed even after that time because ofMSCs trapped in the lung
and activated by microenvironmental stimuli to express the anti-in-
flammatory factor tumor necrosis factor alpha (TNF-a)-induced pro-
tein 6 (TSG-6), which reached myocardial tissue with positive effects.
Interestingly, most of the cells were cleared from the circulation in
5 min and trapped in the lungs with a half-life of 24 h. The authors
also reported that a small amount (less than 3%) of MSCs reappeared
in the circulation after lung localization, suggesting a second wave of
cells that were then found in other tissues. A comparison of cell dis-4 Molecular Therapy: Methods & Clinical Development Vol. 14 Septembtribution 15min after both i.v. and i.a. infusion indicated that the lung
was the main organ of distribution; however, after i.a. delivery, more
cells could reach the brain, heart, liver, and kidneys, which confirmed
the findings of Wang et al.50
Cancers have also been reported as pathological conditions capable of
influencing MSC biodistribution.52,53 A paradigmatic example of this
was recently reported by a study in which near-infrared (NIR) fluo-
rescent nanoparticles were used to track the distribution of i.v.-deliv-
ered bone marrow MSCs for the treatment of brain tumors. In vivo
imaging, histology, and real-time PCR showed that NIR fluorescent
labeling revealed a peculiar distribution after systemic injection.
MSCs were first detected in the lungs within 30 min after transplan-
tation, and they remained there for up to 4 days; however, the signal
gradually decreased in the lungs and increased in the liver and spleen
starting from 4 h after administration and lasting for up to 7 days. The
distribution pattern of the migrated MSCs was similar in normal and
tumor-bearing mice, although there was a significantly higher pres-
ence of labeled MSCs in the brains of the cancer group, with a brain
tropism that appeared to be proportionally inverse to the lung local-
ization.54 These data indicate that an intravascular distribution of
MSCs can reach brain cancer in the presence of blood-brain barrier
(BBB) leakage55: active or passive homing mechanisms driven by
injury and inflammation could explain the migration of the cells
across the BBB. By labeling rat marrow MSCs with intracellular
superparamagnetic iron oxide (SPIO), Cheng et al.56 focused on cell
survival and engraftment in a rat model of traumatic brain injury;
MSCs were monitored by advanced MRI able to track cells after ste-
reotaxic injection. The authors demonstrated migration of labeled
cells near the lesion area until the third week after injection.56
Although the liver has been reported as the target organ under steady-
state conditions, liver diseases may influence MSC distribution. Kim
et al.57 used different cell labels (SPIO and metal nanoparticles
[MNPs]) detected by MRI to monitor MSC implantation, homing,
and differentiation in a rat liver cirrhosis model. After 7 days from in-
trasplenic cell infusion, 3-T MRI tracking and immunohistochem-
istry revealed liver accumulation of MSCs around the fibrous septa,
suggesting possible mechanical trapping by portal blood flow as a
promoting factor for the liver inlet.57 Wu et al.58 used biolumines-
cence and MRI to track MSCs that internalized poly(ethylene
glycol)-block-poly(l-aspartic acid)-grafted polyethylenimine (PAI)-
SPION-plasmid DNA (pDNA). In this case, the combination of
bioluminescence and MRI resulted in an efficient and noninvasive
in vivo imaging tool to track transplanted cells in a liver injury model.
After superior mesenteric vein injection, labeled MSCs were distrib-
uted into the liver for up to 10 days, specifically in the sinusoids of
periportal areas, underlying the tropism of these cells for diseased tis-
sues that was associated with a therapeutic benefit.58
Local Delivery of MSCs Is More Appropriate for In Situ Therapy.
Considering the variability in biodistribution after intravascular de-
livery and accounting for the fact that local delivery could be appro-
priate for defined indications, several research groups focused theirer 2019
Table 2. Key Findings from Preclinical Studies of MSC Biodistribution
Findings References
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The route of administration and the pulmonary
vessel size influence lung trapping.
35,36
d
Intrinsic MSC properties and microenvironment
cues can affect their biodistribution
37,39
e Immunity plays a role in MSC biodistribution. 40–46,48
f




MSC local delivery is more appropriate for an
in situ focal regenerative effect.
56–60
h
The reported immunogenicity of MSCs allows




MSCs can restore tissues because of their intrinsic
properties and cross-talk with the target
pathological environment.
50–58
j Bone marrow is the most selected source of MSCs. 33–35,37,40,48,50,51,54,56–58,60
k








Combinations of in vivo and ex vivo tracking
techniques provide qualitative and quantitative
data regarding MSC distribution over time.
37,48,54,56–60
Table 3. Factors Influencing the Planning of a Preclinical Biodistribution
Study of MSCs
Pharmacodynamics-Related Factors
Mechanism of action and therapeutic effects
Target disease localization
Pathophysiology of the disease
Microenvironment
Pharmacokinetics-Related Factors
MSC-related: size, source, donor age and culture passages, culture conditions,
and immunogenicity
Non-MSC related: labeling, detection method, animal size, and route of
administration
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Reviewattention on local MSC transplantation. Nam et al.59 introduced a
combination of ultrasound and photoacoustic (US-PA) imaging to
track and quantify labeled gold nanotraced (Au NT) MSCs after
intra-muscular (i.m.) injection into rats. The US-PA demonstrated
that the labeled MSCs can be monitored with high sensitivity and
good cell viability over 1 week, and they could be clearly distinguished
from other cells and tissue, such as hemoglobin and skin.59 Years
later, Hossain et al.60 developed a rodent model to monitor i.m. in-
jected iron oxide-labeled MSCs. MRI and histological analyses were
undertaken in rats after MSC injection and showed a high signal
that progressively increased over the course of 3 weeks, including
adjacent tissue localization. Interestingly, a signal could also be de-
tected in the spleen, indicating that i.m. delivery could also be associ-
ated with broader biodistribution.
Despite a large range of reported delivered doses of MSCs (104–107/
animal), key aspects about MSC biodistribution can be summarized
(Table 2): MSCs are transplantable cells whose biodistribution is
influenced by route of administration, pulmonary vessel size, intrinsic
properties, and microenvironmental cues; MSCs can restore tissues
by their intrinsic properties and the ability to cross-talk with the path-
ological microenvironment; the bone marrow has been the most
selected source for MSCs, and rodents are the appropriate preclinical
model because of their accessibility and the existence of immunode-Molecular Tficient strains; the i.v. route is the most applied preclinical route of
administration because it is minimally invasive and because of its pu-
tative ability to achieve wide tissue distribution, even in combination
with strategies aimed to overcome lung trapping; several in vivo and
ex vivo tracking techniques have been combined to describe MSC dis-
tribution over time in qualitative and quantitative terms; and the
immunogenicity of MSCs allowed preclinical investigations in autol-
ogous, allogeneic, and xenogeneic recipients that considered physio-
logical and pathological states.
Factors Influencing Preclinical MSC Biodistribution Studies
As stated, MSC biodistribution is influenced by different factors that
can be divided in PD- and PK-related factors. The first relates to PD
aspects, such as MoA and the recipient biological environment; the
second relates to MSC and non-MSC properties affecting PK, such
as cell size, cell source, immunological features and labeling, detection
methods, route of administration, and size of the animal model
(Table 3). Robust investigations of these aspects are lacking, partly
because of the difficulty of developing standardized approaches to
their study.61,62 The complexity of this standardization is mostly
due to the high variability of PK- and PD-related factors. Reyes
et al.62 recently reported an algorithm for study design to assess
MSC biodistribution; this decision tree is based on the results ob-
tained from preclinical studies in different species using diverse deliv-
ery routes, cellular labeling, and detection methodologies. Therefore,
in this analysis, we sought to further dissect factors involved in the
setup of anMSC preclinical biodistribution study. Knowledge of these
key factors could lead to better standardization and, above all, more
efficient clinical prediction of the clinical dose and efficacy of MSCs
(Tables 4 and 5).
PD-Related Factors
One of the key factors influencing PD is represented by the MoA and
its related therapeutic effect.17 MSC therapeutic effect is often driven
by different and complex mechanisms, such as the ability of the cell to
differentiate in a defined tissue and/or release active substances
responsible for efficacy.63 This complexity can generate uncertain
identification and selection of the bioactive substances (MSCs or their
released factors), and the efficacy of biomarkers is variable because ofherapy: Methods & Clinical Development Vol. 14 September 2019 5
Table 4. Effect of PD-Related Factors on MSC Biodistribution Studies
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Reviewmany upstream-activated pathways. Knowledge of the MoA ruling
pathway is also essential for selection of the MSC delivery route.
Indeed, if differentiation is the leading process in MoA, then the cells
might bemore effective when directly implanted in their site of action;6 Molecular Therapy: Methods & Clinical Development Vol. 14 Septembconversely, if secretion is prevalent, then cells can be active even when
administered remotely (i.e., by the i.v. route). Another MoA-depen-
dent gap in understanding is the discrepancy between in vitro and
in vivo data; this is particularly true when comparing MSC viability,er 2019
Table 5. Effect of PK-Related Factors on MSC Biodistribution Studies
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a lack of in vitro-in vivo correlation, which, consequently, generates
unpredictable outcomes in terms of clinical efficacy.
A further issue relates to MSC therapeutic targets, which can be local-
ized or widely scattered in the body and influence the selection of a
local versus systemic route of administration.65 That, in turn, influ-
ences the choice of the most appropriate animal model and adequate
tracking methods.66
Other PD factors to be considered are represented by pathophysiolog-
ical aspects involved in the often chaotic background of the target dis-
ease and its related microenvironment. The pathophysiology of the
disease is tightly linked to the type of disease (local or systemic rather
than acute or chronic), the patient’s age (young versus old), and the
type of involved cells and the stage of disease (early or advanced).
These variables may influence the choice of MSC source, cell dou-
blings, number of injected cells, and route of administration. Also,
in this case, the detection and selection of the bioactive substances
and efficacy biomarkers can be modified based on the need to treat
an acute or chronic state rather than a young or old patient.67
The pathologic microenvironment to which MSCs are exposed has
also become progressively more relevant. The abundance of
bystander cells as well as their recruitment and function represent
potent PD-influencing factors.68 Unfortunately, the interactions be-Molecular Ttween MSCs and the in vivo microenvironment are still unclear, as
are the biomarkers indicative of MSC-based responses because of
microenvironment regulation.69 Consequently, there is a need to
select and identify bioactive substances and efficacy biomarkers as
well as account for microenvironment effects by in vitro and in vivo
correlation assays.
PK-Related Factors
PK-related factors can be subdivided into MSC-related and non-
MSC-related factors (Table 5). MSC-related PK factors are related
to the cells themselves (intrinsic factors), and non-MSC factors are
related to the techniques introduced in a biodistribution study
(extrinsic factors).
MSC-Related Factors. A biodistribution study is dependent on cell-
related factors, including the size, the source, the cell doubling, and
the immunogenicity of the cells. One of the intrinsic MSC features
that influences biodistribution is MSC size, especially in terms of
cell diameter. This parameter, dependent on the age and passages
in culture,70 can be responsible for trapping in the lung after systemic
administration.36 A diameter between 20 and 24 mm, which is typical
of administered cells, dictates that most infused cells remain in the
pulmonary region because of their dimension (i.e., they are larger
than the size of pulmonary capillaries), and only a low percentage
of cells reaches the site of injury.35,36 Therefore, MSC biodistribution
is widely influenced by size, which generates an imbalance betweenherapy: Methods & Clinical Development Vol. 14 September 2019 7
Table 6. MSC Tracking Methods
In Vivo Imaging Explanation and Comments
Fluorescence
dye on cellular surface; lipophilic carbocyanine dye
for whole cell; GFP
easy visualization and no transfer to neighboring
cells; possible cytotoxicity; reduction of signal after
mitosis; transfer or phagocytosis of dye to other
cells (false positive signal)
Bioluminescence
luciferase gene report; high follow-up (until 120 days);
high tissue specificity, demanding setup by skilled
staff for cell preparation and imager use
Nuclear magnetic
resonance
paramagnetic nanoparticles (Gd); paramagnetic iron
oxide-based compound (SPIO, MION, MNP, APTS)
high spatial resolution (25–50 mm); non-invasive;
repeatable; clinical setting; high cellular viability;
high costs; and NMR availability
Radiolabeling
18F-fluorodeoxyglucose (18F-FDG); indium-111 (111In)
spatial resolution (2 mm) and short-term follow-up
(until 48 h)
Ex Vivo Assays Explanation and Comments
Immunohistochemistry
selective imaging of antigens (proteins) in cells of a
tissue section by exploiting the principle of specific
antibodies binding to antigens
high sensitivity and specificity; not high-throughput;
protocol optimization required
PCR
amplification of DNA segments
high sensitivity and specificity; quantification method;
cheap, fast, and simple testing; high-throughput
www.moleculartherapy.org
Reviewthe expected and effective value of cells at the target site and the time
needed to reach the target.
It is well known that bone marrow, adipose tissue, and fetal annexes
are the most often used MSC sources because of similarities (and
despite some differences) in morphology, the number of isolated cells,
and the ability to differentiate in tissues.3 The choice of MSC tissue
source is important both for the type of tissue to regenerate and the
biological activity required of the cells in the damaged target tissue.
For example, it is known that adipose tissue and umbilical cord
MSCs give origin to adipogenic,71 chondrogenic,72 and osteogenic73
lineages. MSC sources can also influence basic cellular features such
as surface cellular markers and size.74,75 To date, there is no preferred
source in terms of convenience and quality, but bone marrow is
currently the most used.3,31
The injected MSCs should preferably be derived from young donors
and undergo low culture passages to preserve the proliferation poten-
tial and prevent oxidative stress because increased donor age seems to
be correlated with detrimental effects on proliferation and differenti-
ation abilities.31,76,77 In this regard, the US Food and Drug Adminis-
tration (FDA) suggests that propagation of MSCs in vitro should not
exceed 5 weeks—a time beyond which these cells are supposed to
accumulate mutations.78 Despite the lower tumorigenic potential of
humanMSCs compared with rodentMSCs, the risk of tumorigenicity8 Molecular Therapy: Methods & Clinical Development Vol. 14 Septembafter extensive culture should be considered and could affect the ac-
curacy of a biodistribution study.79
In addition to cell and donor age, culture conditions also influence cell
performance and senescence, consequently affecting the number of
cells administered.80 For example, normoxic atmospheric tension
(21% O2) as well as serum starvation and deprivation of growth fac-
tors promote the generation of free radicals that trigger pathways for
apoptosis and premature aging of cells.81 Additionally, low levels of
oxygen increase biological activities involved in the maintenance of
stemness, mobilization, homing, and promotion of certain differenti-
ation phenotypes.3 Interestingly, the introduction of certain growth
supplements and/or cytokines can alter the immunological profiles
of class I and II HLA antigens, which suggests considerations on
possible host immune reaction.82
As described, two of the reasons for wide diffusion of MSC transplan-
tations are the high degree of safety as well as the low risk of rejection.1
Still, it is important to consider possible donor-related immunoge-
nicity. A positive outcome of MSC transplantation is presumably
due to the cellular immunomodulatory ability that allows the cells
to evade the host’s immune system through immunosuppressive
and immunoprivilege mechanisms.3,49 However, data demonstrate
that MSCs show different distributions when transplanted in an
autologous or allogeneic host,48 with allogeneic cells associated with
significantly lower survival than syngeneic cells. AlthoughMSC xeno-
geneic transplantations are characterized by low immunogenicity, the
risk of adverse events is dependent on the host’s immune response,
which is higher than in autologous or allogeneic settings. Neverthe-
less, porcine MSCs, one of the most used alternatives to human
MSCs, can undergo genetic modifications that further decrease their
hypoimmunogenic potential, allowing them to be fully protected
from the host immune response.83 Although this approach retains
some promise, so far there have been no reports of clinical xenogeneic
MSC transplantation.
Non-MSC-Related Factors. Extrinsic cell-related factors focus on
the variables dependent on the setting of a biodistribution study,
such as labeling, route of administration, animal models, and detec-
tion methods.
The cell labeling and the detection methods are relevant for suitable
MSC tracking. Since the beginning of biodistribution studies, scien-
tists followed the fate of MSCs using ex vivo methods, such as real-
time PCR and histological assays, which are characterized by low
cost, ease of execution, and the ability to be performed after animal
sacrifice. Over time, in vivo imaging has gained favor, permitting im-
mediate and repeatable surveillance of MSCs and providing high
spatial and temporal resolution (Table 6).84 Even if an ideal imaging
method does not exist, it is now possible to select between different
techniques, depending on the experimental requirements, including
bioluminescence, fluorescence, radio-labeling (positron emission to-
mography [PET] and single-photon emission computed tomography
[SPECT]), and MRI; each is characterized by a different specificity,er 2019
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biodistribution should combine both in vivo and ex vivo methods
for better interpretation of the results. Although imaging provides im-
mediate results,85 ex vivo assays increase the accuracy of outcomes
aiming to evaluate sensitivity and specificity.57 In vivomethodologies
require MSC labeling that can alter MSC migratory ability and
viability, which must be evaluated before cell delivery.54
Genetic labeling (e.g., luciferase, b-galactosidase, and GFP) requires
protocol optimization to obtain high levels of transduction that can
delay in vivo administration. This gene labeling is preferred for long-
term studies because detection can be maintained after mitosis,
although it is potentially associated with genetic instability following
transduction. On the contrary, chemical labeling has a shorter duration
than genetic labeling because it is diluted in daughter cells after cell di-
vision. This, therefore,makes chemical labelingmore suitable for short-
term follow-up and also accounts for the lack of a robust proliferative
attitude of MSCs after in vivo injection.62,86 In this context, the chem-
ical label transfer from the originally labeled cells to bystander elements
or to phagocytes producing false positives must be considered.52,87
The choice of animal size is dependent on the preclinical investigation
phases. In early stages, it is preferable to use small animals, whereas
large animals are often required in later stages to mimic the clinical
setting; further, in this way, the route of administration must mimic
the one intended for clinical trial.62 This is important because the
route of administration can influence cell bioavailability. For example,
therapeutic targeting can be prevented after systemic delivery because
of the pulmonary first pass.88
Here we described PK and PD factors that influence MSC bio-
distribution. Because most of the studies were performed while
considering—almost exclusively—PD aspects, we maintain that the
PK aspects need attention. Therefore, the next section is dedicated
to PK evidence after MSC systemic delivery and to the proposal of
a new PK-PD model.
PK-PD Evaluation of MSCs
PK describe the time course of drug disposition after administration,
and PD focuses on the observed effects resulting from delivery of a
drug.89 Preclinical PK-PD studies aim to establish a concentration
range of a drug to exert its pharmacological effect. In this range, no
adverse events should occur, and the drug should be considered
safe. Consequently, monitoring of drug concentration is a key step
when defining a drug regimen, related to both efficacy and safety.90
In this context, preclinical research onMSCs has underscored the dif-
ficulty of exactly knowing the fate and the blood and tissue concentra-
tion of the cells after in vivo administration.91 Indeed, it is difficult to
know how many cells die, engraft,66 and differentiate93 or remain in a
steady-state condition. Therefore, defining the cell number respon-
sible for the intended pharmacological effect represents a challenge.
Like cells, small molecules may also undergo variability in their con-
centrations when they reach the systemic circulation. Although theMolecular TPK of a chemical compound are typically dependent on well-charac-
terized properties during drug development, such as the administra-
tion route, physical chemistry (e.g., solubility, stability), pharmaceu-
tical formulation, and absorption distribution metabolism excretion
(ADME)94 features (e.g., protein binding, passive and active trans-
ports, metabolizing enzymes), MSC biodistribution or PK are influ-
enced by many different factors that are dependent on both the PD
and extrinsic and intrinsic MSC-related factors, which complicates
a biodistribution study.
Physiologically based PK modeling (PBPK) has been introduced dur-
ing drug development, with the aim of predicting the drug disposition
of a candidate compound using preclinical PK data.95 This mathe-
matical approach is currently recognized by regulatory agencies to
simulate the efficacy dose and the related safety margins in humans.96
In this oversimplified framework, the body is divided into compart-
ments that mimic tissues or fluids, and the time course of drug
concentration is described by equations. In the so-called “two-
compartment model,” the central compartment is highly blood
perfused and includes plasma, heart, lungs, liver, and kidneys; the pe-
ripheral compartment is considered less perfused and includes fat,
muscle, and cerebrospinal fluid.97
Attempts to introduce PK models for MSCs are still lacking, and this
represents a major limitation. Applying the two-compartment model
to small molecules, Parekkadan and Milwid1 originally proposed a
PBPK concept for MSCs. On the basis of known kinetics data from
selected publications, the authors presented a two-compartment
model that simplifies the biodistribution of MSCs after i.v. delivery.
This model consists of the central (plasma) and the peripheral (tissue)
compartments, whose PK parameters are K1, the constant rate of
extravasation between plasma and tissue, and K2, the constant rate
of intravasation, with Ri and Rc
98 as injection and clearance rates,
respectively (Figure 1A). This approach is also based on the following
assumptions: (1) MSCs look like inert and spherical (diameter [d] =
20 mm) particles that have no interaction with the host; (2) the cells
contain a fixed concentration of molecules that is equivalent to
100% of the bioactivity; (3) the transport of the single molecule
from the cell directly into the bloodstream is not rate limiting; and
(4) the therapeutic index is directly proportional to the serum concen-
tration profile of the molecules secreted by the MSCs.
In a theoretical engraftment, where it is assumed that, after MSC
transplantation, nearly 100% of the cells remain viable and effective
after infusion, an apparent activity (the unit activity per cell multi-
plied by the number of cells after injection) is maintained over the
time course, and long-term therapeutic action is guaranteed (Fig-
ure 1B). However, based on experimental evidence of MSC i.v. deliv-
ery, a better term is apparent engraftment (Figure 1C).
An apparent engraftment is characterized by a quick infusion of a
dose of a drug (Ri) in the bloodstream so that Ri is considered negli-
gible and the plasma concentration (Cp) of the drug is 1 (Cp = 1). The
clearance rate (Rc) and the rate of intravasation (K2) are higher thanherapy: Methods & Clinical Development Vol. 14 September 2019 9
Figure 1. Pharmacokinetics Analysis of MSCs
(A) Two-compartment pharmacokinetic model of mesenchymal stromal stem cells (MSCs) after intravenous (i.v.) delivery. Ri, injection rate; Rc, clearance rate; K1, rate of
extravasation; K2, rate of intravasation. (B) Theoretical engraftment of MSCs with assumption of 100% cellular viability and activity over time. (C) Apparent engraftment of
MSCs with a decaying retention of 24 h. The apparent activity is considered to be the product of the unit activity per cell and the number of cells remaining after injection. The
analysis is taken from Parekkadan and Milwid.1
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the 2 compartments is practically null, and the MSCs stay in the cen-
tral compartment. Parekkadan and Milwid1 represent the apparent
engraftment as in Figure 1C: theMSCs show a rapid decline of cellular
viability,48,51 which, in turn, affects the time to reach maximal secre-
tion of a molecular mediator (apparent activity), with a short
therapeutic window associated with MSC therapy. Consequently, ac-
cording to this model, the therapeutic activity would be maintained
for 24 h, and, for extended efficacy, multiple administrations with a
range of 24 h would be necessary. This may need to be addressed
by comparative clinical trials in which cells are delivered daily versus
weekly, as is currently done for GVHD treatment.99
Although the model by Parekkadan andMilwid1 still represents a way
to address a basal PBPK-PD100model forMSCs, many aspects need to
be considered to carefully establish a model able to make clinical pre-
dictions about MSCs, their doses, and their schedules in vivo.
Although i.v. administration is the route most applied in preclinical
and early clinical studies, it may not be the best route to allow
MSCs to reach the target organs.57 Therefore, we can suppose that,
by changing the route of administration, the PK parameters of the
two-compartment model will not be completely applicable, possibly
because of lower clearance, a higher apparent activity, and a shift of
the model that may come closer to that of the theoretical engraftment.
Moreover, undefined mechanisms of action and the high connection
of MSCs within the neighboring environment make these cells non-
inert particles whose biological activity can be dependent on many
bioactive circulating factors that are released (directly or indirectly)
by injected MSCs or by other cells (i.e., MSC-activated).101,102
Thus, the bioactive substances to be included in the PK-PD model
are not only limited to the MSC number but also related to either
the levels of soluble factors constitutively released by the cells them-10 Molecular Therapy: Methods & Clinical Development Vol. 14 Septemselves or to substances that may be released by MSCs after in vivo
infusion because of microenvironment conditioning. This aspect
adds a complexity that needs to be addressed by new models, and
the high variability of biomarkers detected needs to be considered
in a novel PK-PD prediction. Consequently, the final apparent activ-
ity will be the result of all of the different biomarkers acting within a
defined time frame and also involving bystander cells.
Therefore, we began to reason a new PK-PD model based on the
described considerations (Figure 2). This model, defined as two func-
tional compartments, is based on the fact that, after infusion, MSCs
can release molecules (cell-related biomarkers) capable of function-
ally influencing bystander cells (i.e., macrophages), which, in turn,
can release bioactive substances that we propose as efficacy bio-
markers of the desired therapeutic effect. Although the cell-related
biomarkers are responsible for the PK activity of the MSCs, the effi-
cacy biomarkers reveal the PD activity. In addition, considering
that microenvironment cues may influence MSC-related biomarker
release, we should consider that the effect of MSCs on bystander cells
could be temporally shifted, affecting the PD of infused cells. To pro-
vide an initial justification for this model, we report the original study
by Németh et al.,30 which aimed to attenuate sepsis after i.v. MSC
administration. The authors describe that MSCs can release prosta-
glandin-E2 (PGE2) (as a cell-related biomarker), which acts on
PGE2 receptors of activated macrophages (PGE2 and E4 receptors),
which induces the release of interleukin-10 (IL-10; an efficacy
biomarker), whose function is then to reduce inflammation by acting
on immune cells. Thus, we represent the cell-related biomarkers,
MSCs and PGE2, in the first two-dimensional graphs of Figure 2
and the efficacy biomarker IL-10 in the second graph. Much of the
data supporting this concept have been reported.103 In the definition
of this proposed two functional compartments model, we also
consider that several complex factors may affect the outcome ofber 2019
Figure 2. Two-Functional-Compartments PK-PD Model in Sepsis
(A) Mesenchymal stromal stem cells (MSCs) are challenged in a sepsis model after i.v. delivery, causing prostaglandin-E2 (PGE2) release, which, in turn, acts on PGE2
receptors on macrophages. Macrophage receptor binding is responsible for the increase in interleukin-10 (IL-10) production and a reduction in serum tumor necrosis factor
alpha (TNF-a). (B) The two-functional-compartments PK-PD model. The PK biomarkers are the MSCs and their secreted molecules leading to the PD effect. The PD
biomarkers are the cytokines as markers of the therapeutic activity. The model is extrapolated startng from data produced by Németh et al.30
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factors) and factors related to the cells themselves (PK-related fac-
tors), as described in the previous paragraph.
Final Considerations
This review focuses on MSC biodistribution, addressing the PK and
PD aspects of these intriguing stromal progenitors, originally re-
ported in the 1960s.104 Considering their safety, MSCs are introduced
into clinical practice for a variety of severe and/or rare pathologic con-
ditions when standard approaches have limitations or are no longer
effective.105 Although this strategy is usual during drug development
in clinical translation, it represents a limiting factor for MSC potential
that often finds end-stage diseases to be counteracted, relying on
unclear PK-PD. Despite the growing applications of MSCs in trials,
much still needs to be addressed regarding their biodistribution, espe-
cially because clinical success of an MSC-based product should
require preclinical research with appropriate PK-PD investigations
in early phases of development to better understand MSC functions
and increase their efficacy in patients. In this way, the progression
of MSC-based therapy toward improved clinical development could
be expedited, and early interruptions or unexpected results in later
phases could be avoided. Currently, of the 800 clinical studies of
MSCs, less than 5% are phase III trials (https://www.clinicaltrials.
gov/; search using the key words MSCs, mesenchymal stem cells,
andMSCs), and only 10MSC-based products have been grantedmar-
ket authorization so far, which suggests that the lack of PK-PD studies
might affect clinical development.106
Robust results from preclinical animal research and novel 3R-
respecting in vitro investigations could provide MSC PK and PDMolecular Thdata that are useful for clinical dose planning in the same way that
has been applied for biologics and small molecules.107 For this reason,
we focused on key PK- and PD-related factors and their associated
variables, which may pave the way for standardization in MSC bio-
distribution research. Some PD factors, including MoA, should be
defined as soon as possible to dissect the role of MSCs in a targeted
disease. Then decisions can be made regarding other PK factors
that could differentially affect biodistribution. Indeed, if PD factors
are mandatory to define both cell-related and efficacy biomarkers,
then PK factors are dependent on those which affects the overall qual-
ity of the study. After these early key points have been established,
preclinical investigations can proceed, and the obtained preclinical
results will validate PK-PD models and allow a realistic preclinical/
clinical prediction.107
This approach may be particularly valuable for diseases like pulmo-
nary disorders,108 including asthma, acute respiratory distress syn-
drome (ARDS), chronic obstructive pulmonary disease109 (COPD),
and idiopathic pulmonary fibrosis (IPF),110–112 which are ranked by
theWorld Health Organization (WHO) as leading causes of death.113
MSCs can represent an attractive optional therapy because of their
regenerative and anti-inflammatory abilities.114 Many studies support
the ability of these cells to convert into airway and epithelial cells115
and to promote lung repair and regeneration through MSC paracrine
release, which is also influenced by extracellular vesicles (EVs).116,117
However, many issues need to be considered before treating patients
with MSCs. Often the pathogeneses of lung disorders are not
completely known, and the molecular target to trigger and the MSC
biodistribution in the damaged tissue need to be considered. Conse-
quently, in this context, it may be difficult to select PD/PK factors,erapy: Methods & Clinical Development Vol. 14 September 2019 11
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an inadequate preclinical-clinical prediction with insufficient
achievement of clinical endpoints.107 Thus, even a novel PK-PD
model may be challenged when adopted for the pulmonary field,
where cell-related and efficacy biomarkers may change based on
the type of lung disease and the involvement of novel biomarkers,
such as EVs, may add complexity because of the involvement of sub-
stances released by EVs.118
In conclusion, we dissected several aspects of PK-PD of MSCs and we
suggest a new model that underscores the importance of PK and PD
for the success of MSC-based therapies that should consider possible
bioactive substances and biomarkers to improve the prediction of a
clinical dosing regimen with higher efficacy.
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